AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1.-23.   (Cancelled)

24.   (Currently Amended) A kit for amplifying sequences of the cystic fibrosis CTFR gene comprising one or more pairs of nucleic acid primers ~~selected from the group consisting of~~ including:

~~5'- GCGGTCCCAAAAGGGTCAGTTGTAGGAAGTCACCAAAG -3' (SEQ ID NO: 3) and~~
~~5'- GCGGTCCCAAAAGGGTCAGTCGATACAGAATATATGTGCC -3' (SEQ ID NO: 4), 5'-~~
~~GCGGTCCCAAAAGGGTCAGTGAATCATTCAGTGGGTATAAGCAG -3' (SEQ ID NO: 5)~~
~~and 5'- GCGGTCCCAAAAGGGTCAGTCTTCAATGCACCTCCTCCC -3' (SEQ ID NO: 6),~~
~~5'- GCGGTCCCAAAAGGGTCAGTAGATACTTCAATAGCTCAGCC -3' (SEQ ID NO: 7)~~
~~and 5'- GCGGTCCCAAAAGGGTCAGTGGTACATTACCTGTATTTTGTTT -3' (SEQ ID~~
~~NO: 8), 5'- GCGGTCCCAAAAGGGTCAGTGTGAATCGATGTGGTGACCA -3' (SEQ ID~~
~~NO: 9) and 5'- GCGGTCCCAAAAGGGTCAGTCTGGTTTAGCATGAGGCGGT -3' (SEQ ID~~
~~NO: 10), 5'- GCGGTCCCAAAAGGGTCAGTTTGGTTGTGCTGTGGCTCCT -3' (SEQ ID~~
~~NO: 11) and 5'- GCGGTCCCAAAAGGGTCAGTACAATACATACAAACATAGTGG -3'~~
~~(SEQ ID NO: 12),~~ 5'- GCGGTCCCAAAAGGGTCAGTGAAAGTATTTATTTTTTCTGGAAC
-3' (SEQ ID NO: 13) and 5'-
GCGGTCCCAAAAGGGTCAGTGTGTGTAGAATGATGTCAGCTAT -3' (SEQ ID NO: 14),
~~5'- GCGGTCCCAAAAGGGTCAGTCAGATTGAGCATACTAAAAGTG -3' (SEQ ID NO:~~
~~15) and 5'- GCGGTCCCAAAAGGGTCAGTTACATGAATGACATTTACAGCA -3' (SEQ ID~~
~~NO: 16), 5'- GCGGTCCCAAAAGGGTCAGTAAGAACTGGATCAGGGAAGA -3' (SEQ ID~~
~~NO: 17) and 5'- GCGGTCCCAAAAGGGTCAGTTCCTTTTGCTCACCTGTGGT -3' (SEQ ID~~
~~NO: 18), 5'- GCGGTCCCAAAAGGGTCAGTGGTCCCACTTTTTATTCTTTTGC -3' (SEQ~~
~~ID NO: 19) and 5'- GCGGTCCCAAAAGGGTCAGTTGGTTTCTTAGTGTTTGGAGTTG -3'~~
~~(SEQ ID NO: 20), 5'- GCGGTCCCAAAAGGGTCAGTTGGATCATGGGCCATGTGC -3'~~
~~(SEQ ID NO: 21) and 5'- GCGGTCCCAAAAGGGTCAGTACTACCTTGCCTGCTCCAGTGG~~

~~-3'-(SEQ ID NO: 22), 5'- GCGGTCCCAAAAGGGTCAGTAGGTAGCAGCTATTTTTATGG--~~

~~3'-(SEQ ID NO: 23) and 5'- GCGGTCCCAAAAGGGTCAGTTAAGGGAGTCTTTTGCACAA~~

~~-3'-(SEQ ID NO: 24), 5'- GCGGTCCCAAAAGGGTCAGTGCAATTTTGGATGACCTTC-3'~~

~~(SEQ ID NO: 25) and 5'- GCGGTCCCAAAAGGGTCAGTTAGACAGGACTTCAACCCTC-3'~~

~~(SEQ ID NO: 26), 5'- GCGGTCCCAAAAGGGTCAGTGGTGATTATGGGAGAACTGG-3'~~

~~(SEQ ID NO: 27) and 5'- GCGGTCCCAAAAGGGTCAGTATGCTTTGATGACGCTTC-3'~~

~~(SEQ ID NO: 28), 5'- GCGGTCCCAAAAGGGTCAGTTTCATTGAAAAGCCCGAC-3' (SEQ~~

~~ID NO: 29) and 5'- GCGGTCCCAAAAGGGTCAGTCACCTTCTGTGTATTTTGCTG-3'~~

~~(SEQ ID NO: 30), and 5'-~~

~~GCGGTCCCAAAAGGGTCAGTAAGTATTGGACAACTTGTTAGTCTC-3' (SEQ ID NO:~~

~~31) and 5'- GCGGTCCCAAAAGGGTCAGTCGCCTTTCCAGTTGTATAATTT-3' (SEQ ID~~

~~NO: 32),~~

in an amount sufficient to perform a polymerase chain reaction amplification of a nucleic acid sample.

25.   (Currently Amended) The kit of claim 24, wherein said one or more pairs of nucleic acid primers is five pairs of nucleic acid primers ~~and said five pairs of primers include SEQ ID NOs: 13 and 14~~.

26.   (Currently Amended) The kit of claim 24, wherein said one or more pairs of nucleic acid primers is ten pairs of nucleic acid primers ~~and said ten pairs of primers include SEQ ID NOs: 13 and 14~~.

27.   (Currently Amended) The kit of claim 24, wherein said one or more pairs of nucleic acid primers is fifteen pairs of nucleic acid primers ~~and said fifteen pairs of primers include SEQ ID NOs: 13 and 14~~.

28.   (New) The kit of claim 24, further comprising one or more pairs of nucleic acid primers selected from the group consisting of:

5'- GCGGTCCCAAAAGGGTCAGTTGTAGGAAGTCACCAAAG -3' (SEQ ID NO: 3) and 5'- GCGGTCCCAAAAGGGTCAGTCGATACAGAATATATGTGCC -3' (SEQ ID NO: 4), 5'- GCGGTCCCAAAAGGGTCAGTGAATCATTCAGTGGGTATAAGCAG -3' (SEQ ID NO: 5) and 5'- GCGGTCCCAAAAGGGTCAGTCTTCAATGCACCTCCTCCC -3' (SEQ ID NO: 6), 5'- GCGGTCCCAAAAGGGTCAGTAGATACTTCAATAGCTCAGCC -3' (SEQ ID NO: 7) and 5'- GCGGTCCCAAAAGGGTCAGTGGTACATTACCTGTATTTTGTTT -3' (SEQ ID NO: 8), 5'- GCGGTCCCAAAAGGGTCAGTGTGAATCGATGTGGTGACCA -3' (SEQ ID NO: 9) and 5'- GCGGTCCCAAAAGGGTCAGTCTGGTTTAGCATGAGGCGGT -3' (SEQ ID NO: 10), 5'- GCGGTCCCAAAAGGGTCAGTTTGGTTGTGCTGTGGCTCCT -3' (SEQ ID NO: 11) and 5'- GCGGTCCCAAAAGGGTCAGTACAATACATACAAACATAGTGG -3' (SEQ ID NO: 12), 5'- GCGGTCCCAAAAGGGTCAGTCAGATTGAGCATACTAAAAGTG -3' (SEQ ID NO: 15) and 5'- GCGGTCCCAAAAGGGTCAGTTACATGAATGACATTTACAGCA -3' (SEQ ID NO: 16), 5'- GCGGTCCCAAAAGGGTCAGTAAGAACTGGATCAGGGAAGA -3' (SEQ ID NO: 17) and 5'- GCGGTCCCAAAAGGGTCAGTTCCTTTTGCTCACCTGTGGT -3' (SEQ ID NO: 18), 5'- GCGGTCCCAAAAGGGTCAGTGGTCCCACTTTTTATTCTTTTGC -3' (SEQ ID NO: 19) and 5'- GCGGTCCCAAAAGGGTCAGTTGGTTTCTTAGTGTTTGGAGTTG -3' (SEQ ID NO: 20), 5'- GCGGTCCCAAAAGGGTCAGTTGGATCATGGGCCATGTGC -3' (SEQ ID NO: 21) and 5'- GCGGTCCCAAAAGGGTCAGTACTACCTTGCCTGCTCCAGTGG -3' (SEQ ID NO: 22), 5'- GCGGTCCCAAAAGGGTCAGTAGGTAGCAGCTATTTTTATGG -3' (SEQ ID NO: 23) and 5'- GCGGTCCCAAAAGGGTCAGTTAAGGGAGTCTTTTGCACAA -3' (SEQ ID NO: 24), 5'- GCGGTCCCAAAAGGGTCAGTGCAATTTTGGATGACCTTC -3' (SEQ ID NO: 25) and 5'- GCGGTCCCAAAAGGGTCAGTTAGACAGGACTTCAACCCTC -3' (SEQ ID NO: 26), 5'- GCGGTCCCAAAAGGGTCAGTGGTGATTATGGGAGAACTGG -3' (SEQ ID NO: 27) and 5'- GCGGTCCCAAAAGGGTCAGTATGCTTTGATGACGCTTC -3' (SEQ ID NO: 28), 5'- GCGGTCCCAAAAGGGTCAGTTTCATTGAAAAGCCCGAC -3' (SEQ ID NO: 29) and 5'- GCGGTCCCAAAAGGGTCAGTCACCTTCTGTGTATTTTGCTG -3' (SEQ ID NO: 30), and 5'-

GCGGTCCCAAAAGGGTCAGTAAGTATTGGACAACTTGTTAGTCTC -3' (SEQ ID NO: 31) and 5'- GCGGTCCCAAAAGGGTCAGTCGCCTTTCCAGTTGTATAATTT -3' (SEQ ID NO: 32).